Improvement amphotericin activity experimental cryptococcosis incorporation specific immunoliposomes Cryptococcosis opportunistic infection responsible increased morbidity mortality patients acquired immunodeficiency syndrome high toxicity antifungal agent cryptococcosis amphotericin AMB accounts need new treatments patients acquired immunodeficiency syndrome high relapse rate cryptococcosis Drug targeting alternate treatments immunoglobulin anti-Cryptococcus neoformans monoclonal antibody protective experimental cryptococcosis mice specific AMB liposomes therapeutic index drug purpose vitro vivo experiments specificities activities liposomes control immunoliposomes nonrelated monoclonal antibody immunoliposomes small unilamellar vesicles immunoliposomes yeast cells liposomes neoformans vivo mice infection injection AMB mg/kg body weight liposomes dose AMB AMB nontargeted liposomes control immunoliposomes None mice control treatments AMB mind kind therapy knowledge antigenic type infecting organism results specific small doses AMB efficacy AMB alternative use doses AMB 